We are contrasting ANI Pharmaceuticals Inc. (NASDAQ:ANIP) and Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) on their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership. They both are Biotechnology companies, competing one another.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals Inc.	201.58M	3.92	15.34M	1.18	54.82
Paratek Pharmaceuticals Inc.	17.12M	10.81	112.36M	-3.64	0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 shows us the net margins, return on assets and return on equity of both businesses.

	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals Inc.	7.61%	0.1%	0%
Paratek Pharmaceuticals Inc.	-656.31%	-132.5%	-44.6%

Volatility & Risk

A 2.41 beta indicates that ANI Pharmaceuticals Inc. is 141.00% more volatile compared to Standard & Poor’s 500. Paratek Pharmaceuticals Inc.’s 1.71 beta is the reason why it is 71.00% more volatile than Standard & Poor’s 500.

Liquidity

3.3 and 2.5 are the respective Current Ratio and a Quick Ratio of ANI Pharmaceuticals Inc. Its rival Paratek Pharmaceuticals Inc.’s Current and Quick Ratios are 11.4 and 11.4 respectively. Paratek Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than ANI Pharmaceuticals Inc.

Analyst Recommendations

Ratings and Recommendations for ANI Pharmaceuticals Inc. and Paratek Pharmaceuticals Inc. can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
ANI Pharmaceuticals Inc.	0	0	3	3.00
Paratek Pharmaceuticals Inc.	0	0	4	3.00

ANI Pharmaceuticals Inc.’s average price target is $75.67, while its potential upside is 13.55%. Competitively Paratek Pharmaceuticals Inc. has an average price target of $21.25, with potential upside of 272.15%. The information presented earlier suggests that Paratek Pharmaceuticals Inc. looks more robust than ANI Pharmaceuticals Inc. as far as analyst belief.

Institutional & Insider Ownership

Roughly 81.8% of ANI Pharmaceuticals Inc. shares are owned by institutional investors while 77.7% of Paratek Pharmaceuticals Inc. are owned by institutional investors. Insiders owned 2.1% of ANI Pharmaceuticals Inc. shares. Insiders Comparatively, owned 3.1% of Paratek Pharmaceuticals Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
ANI Pharmaceuticals Inc.	6.15%	20.06%	15.86%	11.7%	5.74%	43.31%
Paratek Pharmaceuticals Inc.	-6.09%	0.67%	-8.98%	-32.44%	-46.95%	32.36%

For the past year ANI Pharmaceuticals Inc. has stronger performance than Paratek Pharmaceuticals Inc.

Summary

ANI Pharmaceuticals Inc. beats Paratek Pharmaceuticals Inc. on 9 of the 12 factors.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for pain; Propafenone to treat arrhythmia; Propranolol ER and Inderal LA for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.